Conferences
Breast Cancers
GI Cancers
Gynecologic Cancer
Immunology News
Multiple Myeloma
Hematology
Lymphoma
Leukemia
Lung Cancers
Melanoma
Prostate Cancer
Urology
CLL
Precision Medicine
Supportive Care
More...
Giants Cancer Care

Dr. Hudis on the CALGB 40601 Study in Breast Cancer

Clifford A. Hudis, MD
Published Online: Thursday, June 20, 2013
Clifford A. Hudis, MD, ASCO President-Elect and chief of the Breast Cancer Medicine Service and attending physician at Memorial Sloan-Kettering Cancer Center in New York, discusses the findings of the CALGB 40601 study examining the neoadjuvant treatment of HER2-positive breast cancer.

The CALGB 40601 study was a randomized phase III trial looking at paclitaxel in combination with trastuzumab, lapatinib, or both for the neoadjuvant treatment of HER2-positive breast cancer. The trial found that the combination of therapies is superior to one or the other alone, Hudis notes.

The second study, presented as a companion study, looked at the rate of conversation from mastectomy to lumpectomy following treatment. The findings from this portion of the study were particularly interesting because it was the first clinical demonstration that neoadjuvant downstaging in HER2-positive disease can increase the rate of breast conservation.

<<< View more from the 2013 ASCO Annual Meeting

Online CME Activities
Free CME from PER
Advances in Multiple Myeloma
Cancer Summaries and Commentaries™: Update from Chicago: Castrate Resistant Prostate Cancer and Advanced Melanoma
Community Practice Connections™: Novel Perspectives in Personalizing EGFR-Targeted Therapy in NSCLC: Frontline and Overcoming Resistance
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Gynecologic Cancers
More Reading
 
$auto_registration$